Search Bar & Filters
Found 23 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating whether less frequent dosing of pembrolizumab after six months of standard treatment is safe and effective for patients with advanced non-small cell lung cancer NSCLC. Pembrolizumab, an immunotherapy targeting the PD-1 receptor, has improved outcomes in NSCLC, but current dosing every six weeks for up to two years may result in overtreatment. This UK phase III trial aims to find if reducing dose frequency can maintain effectiveness while improving quality of life and lowering costs. Participants who have received six months of pembrolizumab, with or without chemotherapy, and plan to continue treatment will be randomized to receive pembrolizumab intravenously every six weeks control or every twelve weeks initially. If the 12-week dosing is found to be not less effective, additional groups receiving doses every nine, fifteen, and eighteen weeks will be included. Patients who experience disease progression while on reduced frequency dosing can return to the standard six-week schedule. Throughout the study, participants will be monitored for overall survival at 18 months from randomization, along with other outcomes such as progression-free survival, response rate, duration of response, and adverse events over two years. The study involves regular hospital visits for treatment and assessments, and the results may lead to safer, more convenient treatment options for NSCLC patients. The total participation time varies depending on individual treatment and follow-up schedules.
Actively Recruiting
Researchers are studying the effectiveness and safety of combining inavolisib with a cyclin-dependent kinase 4 and 6 inhibitor CDK46i and letrozole compared to placebo with CDK46i and letrozole. This study focuses on adults with endocrine-sensitive PIK3CA-mutated hormone receptor-positive, HER2-negative advanced breast cancer. The trial is a phase III, randomized, double-blind, placebo-controlled study aiming to improve first-line treatment options for this condition. Participants will be randomly assigned to receive either oral inavolisib once daily alongside letrozole and a CDK46 inhibitor or a matching placebo with letrozole and CDK46 inhibitor. The CDK46 inhibitor is given on either days 1-21 or days 1-28 of each 28-day treatment cycle. Both groups will follow this treatment regimen throughout the study period. During the trial, participants will be monitored regularly to assess progression-free survival, overall survival, and various measures of treatment response and quality of life, including pain and physical function. Safety will be closely tracked by recording adverse events and treatment-related symptoms using patient-reported outcomes. The study may last up to seven years, including long-term follow-up to evaluate the effects of the treatments over time.
Actively Recruiting
Researchers are evaluating the safety, usability, implantation accuracy, and effectiveness of the MINIject S device in people with open angle glaucoma. This international, multi-center study has two parts the first part compares three different investigational insertion tools to find the best one for placing the MINIject implant. In the second part, the chosen insertion tool is tested in a larger group of patients with both open angle glaucoma and operable cataracts undergoing combined glaucoma and cataract surgery. Participants will receive the MINIject S implant placed in the supraciliary space using one of the investigational insertion tools. In Part 1, each group will use a different version of the insertion tool, with both participants and central readers unaware of which tool is used to ensure unbiased results. In Part 2, the selected insertion tool from Part 1 will be used during combined glaucoma and cataract surgery with intraocular lens implantation. During the study, participants will undergo various assessments including evaluation of correct device placement one week after surgery and ease of use during the procedure. Follow-up visits will occur at 6, 12, and 24 months to monitor visual acuity, intraocular pressure, corneal cell density, and any adverse events. Researchers will also track the need for additional surgeries and changes in glaucoma medications. Participants are expected to adhere to study instructions and attend scheduled examinations throughout the trial, which runs until December 2028.
Actively Recruiting
Researchers are evaluating the combination of bleximenib with venetoclax VEN and azacitidine AZA compared to placebo with VEN and AZA alone for treating adults newly diagnosed with Acute Myeloid Leukemia AML who have specific gene mutations in NPM1 or KMT2A. This phase 3 randomized, double-blind study is designed for participants ineligible for intensive chemotherapy, aiming to understand how these treatments work in this population. Participants will receive treatment in 28-day cycles until disease progression or unacceptable side effects occur. One group will take oral bleximenib alongside oral venetoclax and intravenous or subcutaneous azacitidine, while the other group receives a placebo plus venetoclax and azacitidine. Treatment continues with regular cycles, and the study monitors effects over time. Throughout the study, participants will be assessed for response, including complete remission rates and overall survival, for up to more than four years. Researchers will also track event-free survival, duration and timing of remission, transfusion independence, adverse events, and blood levels of bleximenib. Safety and laboratory tests will be conducted regularly to monitor participant health and treatment effects.
Actively Recruiting
Researchers are evaluating a new treatment called ramantamig-D for people newly diagnosed with multiple myeloma, a type of blood cancer affecting plasma cells. This study compares ramantamig-D with standard treatments that include combinations of daratumumab, bortezomib, lenalidomide, and dexamethasone in participants who are not planned to undergo stem cell transplant as their first therapy. Participants will be randomly assigned to receive either ramantamig-D by subcutaneous injection or one of two standard treatment regimens chosen by their doctor DVRd daratumumab, bortezomib, lenalidomide, and dexamethasone or DRd daratumumab, lenalidomide, and dexamethasone. The study will measure how long participants live without their disease worsening and the percentage achieving a complete response with no detectable cancer cells up to 12 months. During the trial, participants will be monitored for progression-free survival for about 62 months and other outcomes like overall survival and quality of life for up to 100 months. Assessments will include disease response rates, adverse events, and patient-reported outcomes. Participants will have scheduled visits and evaluations to carefully track treatment effects and safety throughout the study.
Actively Recruiting
This research aims to identify preventive treatments that reduce the occurrence, severity, and duration of taste changes caused by talquetamab in people with relapsed or refractory multiple myeloma RRMM who have been exposed to several prior therapies. The study also seeks to better understand the signs and symptoms related to taste changes caused by talquetamab and ramantamig. It is a phase 2, open-label, randomized trial focused on managing oral side effects linked to GPRC5D-related treatments. Participants will receive talquetamab subcutaneously until their disease progresses, they experience unacceptable side effects, or other reasons such as withdrawal of consent or end of study occur. Some participants will also receive one of four different preventive treatments prophylaxis A, B, C, or D starting before talquetamab treatment, while others will receive ramantamig with a single step-up dose followed by continued treatment. The preventive treatments are given orally or topically, depending on the group, and the talquetamab treatment phase can last up to 12 months or longer if beneficial. During the study, participants will undergo regular assessments including taste tests, quality of life questionnaires, and oral health evaluations to measure the presence and severity of taste changes and other oral toxicities. Researchers will monitor treatment responses, adverse events, and changes in body weight and body mass index. The study will continue measuring these outcomes up to 36 months, with safety and quality of life monitored throughout. Participants will be followed until disease progression, unacceptable toxicity, or study completion.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.
Actively Recruiting
Researchers are studying a treatment for adults with muscle-invasive bladder cancer, a condition where cancer has spread into the muscle wall of the bladder. The usual approach involves chemotherapy followed by bladder removal surgery, which can cause significant long-term changes. This study focuses on using a combination of enfortumab vedotin and pembrolizumab to help people keep their bladder, especially for those who respond well to this therapy and wish to avoid surgery. Participants will receive infusions of enfortumab vedotin on the 1st and 8th days of every 3-week cycle, along with pembrolizumab on the 1st day of each cycle. Treatment continues unless the cancer worsens, does not improve after 9 cycles, or if other medical reasons arise. Those whose cancer does not respond may need surgery, radiotherapy, or chemotherapy. The study monitors safety and tumor status regularly during these cycles. Throughout the study, participants will have safety checks at each visit, tumor assessments at some visits, and medical monitoring. After stopping treatment, health checks and scans occur every 3 months for 2 years, then every 6 months for up to 5 years if the cancer remains stable. Once cancer progresses, scans stop, but telephone health checks continue every 3 months. The main outcomes measured are the rate of complete response to treatment and the duration participants keep their bladder intact over two years.
Actively Recruiting
Researchers are evaluating the investigational medicine BI 764524 for adults with moderate to severe non-proliferative diabetic retinopathy, an eye condition related to diabetes. The study aims to determine whether BI 764524 helps improve this condition and to identify the best treatment plan. This phase 2 trial randomly assigns participants to five groups to compare different dosing regimens and controls, including a group receiving aflibercept, an approved diabetic retinopathy treatment available only in the USA. Participants receive varying numbers of injections of BI 764524 in one eye over one year, with some visits involving sham injections that mimic the procedure without a needle to maintain blinding. One group receives only sham injections, and another group in the USA receives aflibercept or sham injections. The treatment period lasts 52 weeks, after which researchers evaluate improvements in eye severity and complications. Throughout the 1.5-year study, participants visit the study site at least 16 times for regular eye exams, vision tests, and imaging scans to monitor the eye condition and treatment effects. Researchers assess improvements using the Diabetic Retinopathy Severity Scale and watch for vision-threatening complications. Safety is monitored by tracking any adverse effects. The study helps understand how BI 764524 affects diabetic retinopathy over time.
1-10 of 23
1